Antiviral Therapy of Chronic Viral Hepatitis

Di Bisceglie, Adrian M.; Hoofnagle, Jay H.
June 1990
American Journal of Gastroenterology;Jun1990, Vol. 85 Issue 6, p650
Academic Journal
Discusses the antiviral therapy for chronic viral hepatitis. Three major forms of chronic viral hepatitis; Functions of interferons; Advantages of the development of sensitive and specific assays for components of hepatitis viruses in the serum and liver.


Related Articles

  • A Novel Ex Vivo Assay of Interferon-Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. Chau-Ting Yeh; Chao-Wei Hsu; Ming-Ling Chang; I-Shyan Sheen; Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Yi-Cheng Chen; Jeng-Chang Chen // Journal of Infectious Diseases;5/15/2006, Vol. 193 Issue 10, p1365 

    An ex vivo liver slice-culture method was used to develop a novel assay of pretherapy interferon-based suppression. To evaluate its clinical application, 45 consecutive patients with chronic hepatitis C were included. They underwent the ex vivo antiviral assay, followed by a 24-week course of...

  • Short-Term Treatment and Sustained Virologic Response in Two Chronic Hepatitis C Cases. Erol, Serpil; Parlak, Mehmet // Medical Journal of Trakya University / Trakya Universitesi Tip F;2010, Vol. 27 Issue 1, p92 

    The standard treatment for chronic hepatitis C infection is the combination of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in patients infected with genotype-1. In genotype-2 or -3 infections, treatment by either conventional IFN-α and ribavirin or Peg-IFN-α with...

  • Cellular Immune Responses during High-Dose Interferon-α Induction Therapy for Hepatitis C Virus Infection. Barnes, Eleanor; Gelderblom, Huub C.; Humphreys, Isla; Semmo, Nasser; Reesink, Henk W.; Beld, Marcel G. H. M.; van Lier, René A. W.; Klenerman, Paul // Journal of Infectious Diseases;3/15/2009, Vol. 199 Issue 6, p819 

    Background. The effect that high-dose interferon (IFN)-α induction therapy for hepatitis C virus (HCV) infection has on cellular immune responses is currently unknown. Methods. Thirty-one treatment-naive patients with chronic HCV infection received amantadine and ribavirin, combined with 6...

  • Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Alsiö, Åsa; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L.; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, pe22 

    Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load....

  • Is screening for interferon retinopathy in hepatitis C justified? Cuthbertson, F. M.; Davies, M.; McKibbin, M. // British Journal of Ophthalmology;Dec2004, Vol. 88 Issue 12, p1518 

    Background/aim: In the treatment of hepatitis C, the National Institute for Clinical Excellence advocates use of a combination of interferon alit and ribavirin for selected patients. Retinopathy is a well recognised side effect of interferon therapy and is characterised by retinal haemorrhages,...

  • Interferon-γ Production Specific for Hepatitis B Virus Antigen by Intrahepatic T Lymphocytes in Patients with Acute and Chronic Hepatitis B. Kakumu, Shinichi; Ishikawa, Tetsuya; Wakita, Takaji; Voshioka, Kentaro; Takayanagi, Masahiro; Tahara, Hirofumi; Kusakabe, Atsuhiko // American Journal of Gastroenterology;Jan1994, Vol. 89 Issue 1, p92 

    Objectives: Studies were undertaken to determine whether intrahepatic lymphocytes have a greater cellular immune response specific for hepatitis B virus (HBV) antigen than peripheral blood lymphocytes in HBV- infected man. Methods: HB nucleocapsid anti-gen-stimulated...

  • The Breakthrough Phenomenon during α-Interferon Therapy of Chronic Hepatitis C: Incidence, Management, and Outcome. Lebovics, Edward; Lantin, Jose; Chaurushia, Gaurang; Dworkin, Brad M.; Casellas, Ana; Rosenthal, William S. // American Journal of Gastroenterology;Jun1995, Vol. 90 Issue 6, p951 

    Objectives: Some patients treated with α-interferon (α-IFN) for chronic hepatitis C (CHC) initially respond with normalization of ALT only to encounter a rise in ALT while still on the drug. This phenomenon is called breakthrough (BT). We reviewed our experience with BT to clarify its...

  • Side effects of antiviral therapy.  // New Zealand Doctor;7/4/2012, p44 

    The article discusses the side effects of antiviral therapy for chronic viral hepatitis. It describes the early and late phase side effects of antiviral therapy and explains the contraindications to pegylated interferon plus ribavirin treatment. It refers to urgency, likelihood of response and...

  • Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. Singh Rehan, Harmeet; Manak, Seema; Yadav, Madhur // Indian Journal of Pharmacology;Sep/Oct2014, Vol. 46 Issue 5, p490 

    Objective: To document the signifi cant sustained virological response with supervised conventional interferon α and ribavirin therapy in hepatitis C virus (HCV)-infected patients, this study was planned. Materials and Methods: Sixty chronic hepatitis C naive patients were included in this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics